Your browser doesn't support javascript.
loading
Allogeneic stem cell transplantation in the treatment of acute myeloid leukemia: An overview of obstacles and opportunities.
Chen, Yong-Feng; Li, Jing; Xu, Ling-Long; Gaman, Mihnea-Alexandru; Zou, Zhen-You.
Afiliación
  • Chen YF; Department of Basic Medical Sciences, School of Medicine of Taizhou University, Taizhou University, Taizhou 318000, Zhejiang Province, China.
  • Li J; Department of Histology and Embryology, North Sichuan Medical College, Nanchong 637000, Sichuan Province, China.
  • Xu LL; Department of Hematology, Taizhou Central Hospital, Taizhou 318000, Zhejiang Province, China.
  • Gaman MA; Faculty of Medicine, "Carol Davila" University of Medicine and Pharmacy, Bucharest 050474, Romania. mihneagaman@yahoo.com.
  • Zou ZY; Department of Scientific Research,Brain Hospital of Guangxi Zhuang Autonomous Region, Liuzhou 545005, Guangxi Zhuang Autonomous Region, China.
World J Clin Cases ; 11(2): 268-291, 2023 Jan 16.
Article en En | MEDLINE | ID: mdl-36686358
As an important treatment for acute myeloid leukemia, allogeneic hematopoietic stem cell transplantation (allo-HSCT) plays an important role in reducing relapse and improving long-term survival. With rapid advancements in basic research in molecular biology and immunology and with deepening understanding of the biological characteristics of hematopoietic stem cells, allo-HSCT has been widely applied in clinical practice. During allo-HSCT, preconditioning, the donor, and the source of stem cells can be tailored to the patient's conditions, greatly broadening the indications for HSCT, with clear survival benefits. However, the risks associated with allo-HSCT remain high, i.e. hematopoietic reconstitution failure, delayed immune reconstitution, graft-versus-host disease, and post-transplant relapse, which are bottlenecks for further improvements in allo-HSCT efficacy and have become hot topics in the field of HSCT. Other bottlenecks recognized in the current treatment of individuals diagnosed with acute myeloid leukemia and subjected to allo-HSCT include the selection of the most appropriate conditioning regimen and post-transplantation management. In this paper, we reviewed the progress of relevant research regarding these aspects.
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: World J Clin Cases Año: 2023 Tipo del documento: Article País de afiliación: China Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: World J Clin Cases Año: 2023 Tipo del documento: Article País de afiliación: China Pais de publicación: Estados Unidos